Previous 10 | Next 10 |
2023-12-19 12:14:25 ET More on Atara Biotherapeutics Atara Biotherapeutics: Market Overreaction To Failed MS Study Creates Buy Opportunity Atara's Balancing Act: Innovation On A Fiscal Tightrope Atara Biotherapeutics, Inc. (ATRA) Q3 2023 Earnings Call Transcript ...
ATA3431 Preclinical Data Demonstrates Superior In Vivo Anti-tumor Activity, Survival, and Functional Persistence Compared to Autologous CAR-T Benchmark No Observed Treatment-Related Toxicities or Alloreactivity Data Supports Advancement Into IND-Enabling Studies Atara ...
2023-11-30 10:11:39 ET DENVER, Colo., Nov. 30, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Atara Biotherapeutics Inc (NASDAQ: ATRA), Minim Inc (NASDAQ: MINM), Altamira Therapeutics Ltd (NASDAQ: CYTO),...
Combined Analysis That Includes First Reported Data from Multicohort Phase 2 EBVision Trial Consistent with Previous Single-Center Experience Pooled Analysis Shows 77.8% Objective Response Rate (ORR) in 18 EBV+ CNS PTLD Patients, Including First Line PTLD Setting and Promising Long-Term S...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Exe...
2023-11-22 15:14:10 ET Penny stocks offer investors the chance to get in on the ground floor of small companies with growth potential. They also offer high-volatility trading opportunities daily that can see huge moves of 100% or more. Penny stocks do carry higher risk. However, som...
2023-11-17 13:32:10 ET Ever wonder what signals to look for in the stock market today? Let’s talk about insider buying – a goldmine of clues that could lead you to the next prospect to add to your list of penny stocks to watch. Why Insider Buying Matters in Penny S...
2023-11-17 12:26:47 ET DENVER, Colo., Nov. 17, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Altamira Therapeutics Ltd (NASDAQ: CYTO), Gap Inc (NYSE: GPS), Twist Bioscience Corp (NASDAQ: TWST), S...
2023-11-15 13:09:37 ET More on Atara Biotherapeutics Atara Biotherapeutics: Market Overreaction To Failed MS Study Creates Buy Opportunity Atara's Balancing Act: Innovation On A Fiscal Tightrope Atara Biotherapeutics, Inc. (ATRA) Q3 2023 Earnings Call Transcript ...
2023-11-15 12:52:53 ET Penny stocks are often priced under $5 per share. They attract traders seeking big gains. But, these stocks also carry significant risks. One smart strategy is to track insider trading via SEC filings. Insiders, like directors and officers, often access vital, non...
News, Short Squeeze, Breakout and More Instantly...
Atara Biotherapeutics Inc. Company Name:
ATRA Stock Symbol:
NASDAQ Market:
Atara Biotherapeutics Inc. Website:
ATA3219 Demonstrates Complete CD19-Specific B-Cell Depletion Against Systemic Lupus Erythematosus and Multiple Sclerosis Patient Peripheral Blood Mononuclear Cells ATA3219 Induces Lower Levels of Pro-Inflammatory Cytokines While Maintaining Cytotoxic Potency Compared With Autologous Bench...
First Allogeneic T-Cell Therapy BLA Submission to U.S. Food and Drug Administration If Approved, Tab-cel Would be First Approved Therapy in U.S. for EBV+ PTLD Acceptance of BLA Will Trigger $20 Million Milestone Payment from Pierre Fabre Laboratories, with Potential for Additional...
Tab-cel ® U.S. BLA on Track for Submission in Q2 2024 Initiation of ATA3219 Lupus Nephritis Study Expected in Q4 2024, with Initial Clinical Data Expected in H1 2025 Initiation of New ATA3219 Cohort Without Lymphodepletion in Severe Systemic Lupus Erythematosus Planned fo...